Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy
Authors:
- Charles BobinCBCharles Bobin
- Yasmine IddirYIYasmine Iddir
- Charlotte ButterworthCBCharlotte Butterworth
- Julien Masliah-PlanchonJMJulien Masliah-Planchon
- Alexandra Saint-CharlesASAlexandra Saint-Charles
- Angela BelliniABAngela Bellini
- Jaydutt BhalshankarJBJaydutt Bhalshankar
- Gaelle PierronGPGaelle Pierron
- Valérie CombaretVCValérie Combaret
- Valéry AttignonVAValéry Attignon
- Nicolas AndréNANicolas André
- Nadège CorradiniNCNadège Corradini
Open Access
- 24 May 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (15) , 3316-3328
Abstract
Purpose: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell–specific genetic alterations in patients with neuroblastoma. Experimental Design: Eighteen patients with relapsing neuroblastoma having received lorlatinib, a third-generation ALK inhibitor, were identified (SACHA national registry and/or in the institution). cfDNA was analyzed at relapse for nine patients and sequentially for five patients (blood/bone marrow plasma) by performing whole-genome sequencing library construction followed by ALK-targeted ddPCR of the hotspot mutations [F1174L, R1275Q, and I1170N; variant allele fraction (VAF) detection limit 0.1%] and whole-exome sequencing (WES) to evaluate disease burden and clonal evolution, following comparison with tumor/germline WES. Results: Overall response rate to lorlatinib was 33% (CI, 13%–59%), with response observed in 6/10 cases without versus 0/8 cases with MYCN amplification (MNA). ALK VAFs correlated with the overall clinical disease status, with a VAF < 0.1% in clinical remission, versus higher VAFs (>30%) at progression. Importantly, sequential ALK ddPCR detected relapse earlier than clinical imaging. cfDNA WES revealed new SNVs, not seen in the primary tumor, in all instances of disease progression after lorlatinib treatment, indicating clonal evolution, including alterations in genes linked to tumor aggressivity (TP53) or novel targets (EGFR). Gene pathway analysis revealed an enrichment for genes targeting cell differentiation in emerging clones, and cell adhesion in persistent clones. Evidence of clonal hematopoiesis could be observed in follow-up samples. Conclusions: We demonstrate the clinical utility of combining ALK cfDNA ddPCR for disease monitoring and cfDNA WES for the study of clonal evolution and resistance mechanisms in patients with neuroblastoma receiving ALK-targeted therapy.Keywords
All Related Versions
Funding Information
- Annenberg Foundation
- French National Agency for the Safety of Medicine and Health Products
- Societe Française de Lutte Contre les Cancers et Leucémies de L’enfants et L’adolescent
- Fondation des Entreprises du Medicament
- Association Hubert Gouin Enfance et Cancer
- Fédération Enfants Cancers Santé
- Imagine for Margo
- Les Bagouz à Manon
- Fondation ARC pour la Recherche sur le Cancer
- Institut National Du Cancer (INCa grant PHRC IC2007-09, and INCa grant PRTK 2019-1-RT-02-ICR-1, INCa-DGOS- 4654)
- Agence Nationale de la Recherche (ANR-10-EQPX-03 (Equipex) and ANR-10-INBS-09-08 (France Génomique Consortium))
- Cancéropôle Ile de France
- Joint Transnational Call for Proposals 2017
- Neuroblastoma UK
- Friends of Rosie
This publication has 46 references indexed in Scilit:
- Detection of tumor ALK status in neuroblastoma patients using peripheral bloodCancer Medicine, 2015
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in NeuroblastomaCancer Cell, 2014
- Emergence of New ALK Mutations at Relapse of NeuroblastomaJournal of Clinical Oncology, 2014
- The genetic landscape of high-risk neuroblastomaNature Genetics, 2013
- Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSiftFrontiers in Genetics, 2012
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature, 2008
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008